GPCR — Structure Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.83bn
- $1.39bn
- 30
- 26
- 35
- 20
Annual income statement for Structure Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 15.9 | 37.7 | 52.6 | 103 |
| Operating Profit | -15.9 | -37.7 | -52.6 | -103 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -15.7 | -37.8 | -51.3 | -89.4 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -15.9 | -38 | -51.3 | -89.6 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -15.9 | -38 | -51.3 | -89.6 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -16 | -43.8 | -52.8 | -89.6 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.146 | -0.399 | -0.481 | -0.813 |